Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOE K TUNG

Allopathic & Osteopathic Physicians Dermatology

NPI
1871121509
CMS profile
11284153
Location
PITTSBURGH, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$357,849.39

382 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 5 of 8; records 201–250 of 382 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOE K TUNG

NPI 1871121509 · CMS profile ID 11284153

Allopathic & Osteopathic Physicians / Dermatology

PITTSBURGH, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 8; records 201–250 of 382 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1871121509?year=2025&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOE K TUNG, NPI 1871121509, CMS profile ID 11284153. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 8; records 201–250 of 382 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1871121509?year=2025&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JOE K TUNG, NPI 1871121509, CMS profile ID 11284153. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 8; records 201–250 of 382 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1871121509?year=2025&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JOE K TUNG, NPI 1871121509, CMS profile ID 11284153, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 8; records 201–250 of 382 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1871121509?year=2025&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

382 matching records · $357,849.39 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 382 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 382.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $4,000.0007/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1204585056 CMS
ABBVIE INC. $4,000.0007/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1204585060 CMS
Novartis Pharmaceuticals Corporation $33.4007/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200456811 CMS
UCB, Inc. $115.7407/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224707425 CMS
UCB, Inc. $607.5907/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224707429 CMS
Lilly USA, LLC $1,600.0007/11/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186672423 CMS
UCB, Inc. $15.0007/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224707418 CMS
UCB, Inc. $1,725.0007/10/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224707421 CMS
UCB, Inc. $113.4007/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224707409 CMS
UCB, Inc. $771.9107/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224707413 CMS
E.R. Squibb & Sons, L.L.C. $4,700.0007/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1184972318 CMS
E.R. Squibb & Sons, L.L.C. $14.4207/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1184972320 CMS
Janssen Biotech, Inc. $4.3607/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174641135 CMS
ABBVIE INC. $2,400.0007/01/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1204585052 CMS
E.R. Squibb & Sons, L.L.C. $4.0607/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184972304 CMS
E.R. Squibb & Sons, L.L.C. $4,700.0007/01/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1184972312 CMS
Takeda Pharmaceuticals U.S.A., Inc. $49.9906/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223617102 CMS
Takeda Pharmaceuticals U.S.A., Inc. $74.0306/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223617104 CMS
Takeda Pharmaceuticals U.S.A., Inc. $370.6506/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1223617106 CMS
Takeda Pharmaceuticals U.S.A., Inc. $154.6006/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1223617108 CMS
Takeda Pharmaceuticals U.S.A., Inc. $24.9906/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223617110 CMS
Takeda Pharmaceuticals U.S.A., Inc. $24.8506/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223617112 CMS
Lilly USA, LLC $1,200.0006/27/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1186663401 CMS
Takeda Pharmaceuticals U.S.A., Inc. $315.8106/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1223617090 CMS
Takeda Pharmaceuticals U.S.A., Inc. $24.9906/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223617092 CMS
Takeda Pharmaceuticals U.S.A., Inc. $36.1306/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223617094 CMS
Takeda Pharmaceuticals U.S.A., Inc. $49.9906/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223617096 CMS
Takeda Pharmaceuticals U.S.A., Inc. $74.0306/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223617098 CMS
Takeda Pharmaceuticals U.S.A., Inc. $24.9906/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223617100 CMS
Takeda Pharmaceuticals U.S.A., Inc. $315.8106/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1223617086 CMS
Takeda Pharmaceuticals U.S.A., Inc. $217.5706/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1223617088 CMS
ABBVIE INC. $2,400.0006/25/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1204585048 CMS
Arcutis Biotherapeutics, Inc. $15.6606/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252349763 CMS
Lilly USA, LLC $7,200.0006/25/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186745215 CMS
ABBVIE INC. $82.9206/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204585044 CMS
ABBVIE INC. $124.4606/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204585039 CMS
Arcutis Biotherapeutics, Inc. $17.2506/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252349761 CMS
Lilly USA, LLC $61.9706/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186672421 CMS
Lilly USA, LLC $21.0006/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186718315 CMS
Lilly USA, LLC $20.0006/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186718317 CMS
UCB, Inc. $15.0006/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224707405 CMS
ABBVIE INC. $20.5206/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204585034 CMS
Janssen Scientific Affairs, LLC $24.3106/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174191985 CMS
E.R. Squibb & Sons, L.L.C. $114.8506/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184972322 CMS
Lilly USA, LLC $2,000.0006/17/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186672419 CMS
Arcutis Biotherapeutics, Inc. $1,500.0006/16/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1252349773 CMS
Janssen Biotech, Inc. $350.0006/14/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1174626147 CMS
Janssen Biotech, Inc. $6,300.0006/14/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1174638212 CMS
UCB, Inc. $1,725.0006/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224707401 CMS
E.R. Squibb & Sons, L.L.C. $752.4706/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1184972308 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $486.99 6
PY2022 $1,722.54 21
PY2023 $5,568.17 30
PY2024 $38,486.58 91
PY2025 $357,849.39 382

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $792,108.21 70
PY2024 Recipient $810.69 9
PY2024 Principal investigator $286,911.30 24

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

70 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,529.40 12/31/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIAN
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202532432
Principal investigator 1 Janssen Research & Development, LLC $1,762.00 12/25/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175342497
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $252.00 12/05/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289336
Principal investigator 1 ABBVIE INC. $53,627.70 12/04/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202528492
Principal investigator 1 Janssen Research & Development, LLC $3,007.00 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175342444
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,686.20 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289099
Principal investigator 1 SANOFI US SERVICES INC. $48,105.90 11/21/2025 Non-covered Recipient Entity
University Of Pittsburgh Physicians
A Multinational, Multicenter, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226154702
Principal investigator 1 ABBVIE INC. $29,406.15 11/05/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202521383
Principal investigator 1 ABBVIE INC. $2,008.50 11/05/2025 Non-covered Recipient Entity
UPMC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202521385
Principal investigator 1 ABBVIE INC. $1,614.54 11/04/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202520103
Principal investigator 1 Eli Lilly and Company $8,000.00 11/03/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS No dispute reported 06/30/2026 1187893388
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $61.29 10/30/2025 Non-covered Recipient Entity
UPMC Department Of Dermatology
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235992307
Principal investigator 1 Janssen Research & Development, LLC $1,762.00 10/24/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175342414
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,118.55 10/22/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287321
Principal investigator 1 ABBVIE INC. $1,973.90 10/09/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202515937
Principal investigator 1 ABBVIE INC. $34,632.10 10/09/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202516077
Principal investigator 1 Novartis Pharmaceuticals Corporation $500.85 10/08/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH MEDICAL CENTER MONTEFIORE
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190306387
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,225.50 10/01/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSI
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223286063
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,225.60 10/01/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSI
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223286101
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,047.50 10/01/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286119
Principal investigator 1 Janssen Research & Development, LLC $1,762.00 09/29/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175342428
Principal investigator 1 SANOFI US SERVICES INC. $4,452.00 09/24/2025 Non-covered Recipient Entity
University Of Pittsburgh Medical Center Hillman Cancer Center
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226090172
Principal investigator 1 Janssen Research & Development, LLC $4,126.00 09/08/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175342473
Principal investigator 1 ABBVIE INC. $36,989.10 09/04/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202509838
Principal investigator 1 ABBVIE INC. $101.25 09/03/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202508206
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,604.75 09/03/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284901
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,056.95 08/08/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283961
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,893.55 08/08/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283963
Principal investigator 1 ABBVIE INC. $44,133.80 08/06/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202502953
Principal investigator 1 ABBVIE INC. $1,920.75 08/06/2025 Non-covered Recipient Entity
UPMC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202502955
Principal investigator 1 ABBVIE INC. $398.51 08/05/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202501696
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,058.30 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223283609
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,194.55 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223283649
Principal investigator 1 Janssen Research & Development, LLC $5,814.00 07/28/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175342395
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,544.70 07/18/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223282832
Principal investigator 1 Janssen Research & Development, LLC $17,048.00 07/09/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175342422
Principal investigator 1 ABBVIE INC. $26,441.05 07/02/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202495823
Principal investigator 1 ABBVIE INC. $2,192.60 07/02/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202495945
Principal investigator 1 ABBVIE INC. $2,240.70 07/02/2025 Non-covered Recipient Entity
UPMC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202495947
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,430.30 06/11/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223281076
Principal investigator 1 ABBVIE INC. $17,588.40 06/03/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202488947
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,017.80 05/16/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223279932
Principal investigator 1 ABBVIE INC. $2,089.50 05/07/2025 Non-covered Recipient Entity
UPMC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202482549
Principal investigator 1 ABBVIE INC. $10,540.00 05/07/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202482551
Principal investigator 1 ABBVIE INC. $16,662.40 05/07/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202482553
Principal investigator 1 ABBVIE INC. $3,189.93 05/06/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202481271
Principal investigator 1 SANOFI US SERVICES INC. $69,339.20 05/02/2025 Non-covered Recipient Entity
University Of Pittsburgh Medical Center Hillman Cancer Center
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226090144
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,555.00 04/11/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277926
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,069.95 04/11/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278046
Principal investigator 1 ABBVIE INC. $4,000.00 04/10/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202475868
Principal investigator 1 ABBVIE INC. $13,614.10 04/03/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202471718
Principal investigator 1 ABBVIE INC. $1,772.25 04/03/2025 Non-covered Recipient Entity
UPMC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202472097
Principal investigator 1 ABBVIE INC. $1,358.46 04/03/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202472202
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,431.70 04/02/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223277488
Principal investigator 1 UCB SA $62,602.00 03/21/2025 Non-covered Recipient Entity
University Of Pittsburgh Physicians
A PHASE 3B EXPLORATORY MULTICENTER OPEN-LABEL STUDY TO EVALUATE THE EFFECT OF BIMEKIZUMAB ON GENE EXPRESSION BIOMARKERS IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 1246659114
Principal investigator 1 Janssen Research & Development, LLC $440.00 03/18/2025 Non-covered Recipient Entity
Univ Of Pittsburgh Physicians
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175267654
Principal investigator 1 Janssen Research & Development, LLC $998.00 03/18/2025 Non-covered Recipient Entity
Univ Of Pittsburgh Physicians
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175267793
Principal investigator 1 ABBVIE INC. $1,839.75 03/07/2025 Non-covered Recipient Entity
UPMC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202461524
Principal investigator 1 ABBVIE INC. $18,447.20 03/07/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202461663
Principal investigator 1 ABBVIE INC. $1,877.06 03/06/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202458349
Principal investigator 1 Janssen Research & Development, LLC $3,496.00 03/03/2025 Non-covered Recipient Entity
Univ Of Pittsburgh Physicians
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175267660
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,213.60 03/03/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223275873
Principal investigator 1 ABBVIE INC. $6,185.10 02/06/2025 Non-covered Recipient Entity
UPMC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202447624
Principal investigator 1 ABBVIE INC. $11,351.20 02/06/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202447684
Principal investigator 1 ABBVIE INC. $398.51 02/05/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202444551
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,290.80 02/05/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274889
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,500.00 02/03/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223274695
Principal investigator 1 Novartis Pharmaceuticals Corporation $22,457.22 02/01/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH MEDICAL CENTER MONTEFIORE
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190306389
Principal investigator 1 ABBVIE INC. $3,108.44 01/02/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202434233
Principal investigator 1 Amgen Inc. $18,725.10 01/02/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH MEDICAL CENTER
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246650713